Herlapsa Tablet

Product Description

1. Technical Specifications

2. Product Description

Herlapsa Tablet contains Lapatinib, a dual tyrosine kinase inhibitor that blocks HER2/neu and EGFR receptors. It interferes with tumor cell growth and survival by inhibiting downstream signaling pathways.
It is prescribed for the treatment of HER2-positive advanced or metastatic breast cancer, especially in patients whose disease has progressed after prior therapies (e.g., trastuzumab, anthracyclines, taxanes).
Herlapsa is usually given in combination with capecitabine or letrozole, depending on hormone receptor status.

3. Product Highlights

4. Therapeutic Uses

• Advanced or Metastatic HER2-positive Breast Cancer

  • In combination with Capecitabine for patients with prior trastuzumab and chemotherapy failure.

  • In combination with Letrozole for postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.

5. Side Effects

Common:

• Diarrhea

• Nausea, vomiting, loss of appetite

• Fatigue, weakness

• Skin rash, dryness, itching

• Headache

• Mouth sores

Serious (rare but important):

• Hepatotoxicity (liver damage jaundice, dark urine, itching)

• Cardiac dysfunction (reduced left ventricular ejection fraction, heart failure)

• QT interval prolongation (irregular heartbeat)

• Severe diarrhea & dehydration

• Pulmonary toxicity (interstitial lung disease, pneumonitis)

6. Precautions

• Use only under supervision of an oncologist.

• Liver monitoring: Regular liver function tests required.

• Heart monitoring: Assess cardiac function (LVEF) before and during therapy.

• Electrolyte & ECG monitoring in patients with cardiac risk factors.

• Pregnancy & breastfeeding: Contraindicated. Use contraception during and 1 week after treatment.

• Drug interactions: Avoid grapefruit juice; caution with CYP3A4 inhibitors/inducers.

• Caution in diarrhea management: Use hydration and anti-diarrheal agents early.

• Not for unnecessary usereserved for HER2-positive breast cancer patients.